Home » Stocks » AVIR

Atea Pharmaceuticals, Inc. (AVIR)

Stock Price: $21.32 USD -0.70 (-3.18%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $21.49 +0.17 (0.80%) May 7, 7:43 PM
Market Cap 1.81B
Revenue (ttm) 48.63M
Net Income (ttm) -10.95M
Shares Out 82.74M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $21.32
Previous Close $22.02
Change ($) -0.70
Change (%) -3.18%
Day's Open 21.99
Day's Range 21.15 - 23.26
Day's Volume 1,056,748
52-Week Range 19.70 - 94.17

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial anticipate...

1 week ago - Benzinga

Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting Phase 3 trial to evaluate efficacy and safety of...

1 week ago - GlobeNewsWire

Atea Pharmaceuticals (AVIR) has been struggling lately, but the selling pressure may be coming to an end soon

2 weeks ago - Zacks Investment Research

Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

3 weeks ago - Zacks Investment Research

– Rapid advancement of AT-527 for COVID-19 –

1 month ago - GlobeNewsWire

BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and au...

1 month ago - GlobeNewsWire

High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients

2 months ago - GlobeNewsWire

As the Nasdaq eroded all the gains made this year and turned red due to the tech sell-off, there are still some stocks that have gained more than 50% so far this year.

Other stocks mentioned: COHR, CRTO, FANG, SNBR, TSLA
2 months ago - Zacks Investment Research

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Other stocks mentioned: ADMA, BNTX, LXRX, MRNA
2 months ago - Zacks Investment Research

Chugai obtains exclusive development and marketing rights for AT-527 in Japan from Roche, who has ex-US rights for the treatment of COVID-19 Chugai obtains exclusive development and marketing rights for...

2 months ago - GlobeNewsWire

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: JNJ, LEGN, LLY, NKTX, RHHBY, RNA
2 months ago - GuruFocus

Data underscore key mechanistic features enabling AT-527 to inhibit SARS-CoV-2 viral replication and support current late-stage clinical development program Data underscore key mechanistic features enab...

2 months ago - GlobeNewsWire

Trial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to moderate COVID-19 Trial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to ...

3 months ago - GlobeNewsWire

This could be a key year for these companies' treatment candidates.

Other stocks mentioned: RDHL
3 months ago - The Motley Fool

Atea has a major deal with Roche. Atea just IPO-ed, but it already has $4.4bn in market cap.

3 months ago - Seeking Alpha

Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications

3 months ago - GlobeNewsWire

Atea Pharmaceuticals (AVIR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral ...

4 months ago - GlobeNewsWire

BOSTON, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000® Inde...

4 months ago - GlobeNewsWire

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral ...

5 months ago - GlobeNewsWire

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 mil...

Other stocks mentioned: ALGM, BDSX, GATO, GLTO, LESL, LU, MAX ...
5 months ago - Seeking Alpha

Experienced Financial Executive Brings Leadership and Public Company Expertise Experienced Financial Executive Brings Leadership and Public Company Expertise

6 months ago - GlobeNewsWire

Full Exercise of the Underwriters' Overallotment Brings Additional $45 Million Full Exercise of the Underwriters' Overallotment Brings Additional $45 Million

6 months ago - GlobeNewsWire

Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed.

Other stocks mentioned: ACICU, DSACU, GLTO, LESL, LUXAU, MAX, ROOT
6 months ago - Seeking Alpha

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral ...

6 months ago - GlobeNewsWire

Atea Pharmaceuticals intends to raise $253 million in a U.S. IPO of its common stock. The firm is developing treatments for virus-borne diseases such as Covid-19 and Hepatitis C.

6 months ago - Seeking Alpha

Atea Pharma has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering.

6 months ago - 24/7 Wall Street

Atea Pharmaceuticals Inc., a clinical-stage biotech that specializes in anti-viral therapies, set terms for its initial public offering on Monday with plans to offer 11 million shares priced at $22 to $...

6 months ago - Market Watch

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 30, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AVIR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AVIR stock is "Strong Buy." The 12-month stock price forecast is 82.00, which is an increase of 284.62% from the latest price.

Price Target
$82.00
(284.62% upside)
Analyst Consensus: Strong Buy